MacroGenics, Inc


Date of Investment: 2002
Status: IPO (NASDAQ: MGNX) in 2013
Headquarters: Rockville, Maryland
MacroGenics is a clinical-stage biopharmaceutical company focused on discovering and developing innovative monoclonal antibody-based therapeutics for the treatment of cancer. The Company generates its pipeline of product candidates primarily from its proprietary suite of next-generation antibody-based technology platforms, which have applicability across broad therapeutic domains.